50 countries have already expressed interest in purchasing the Sputnik V vaccine, developed by Russia’s Gamaleya Research Institute. The Russian Direct Investment Fund (RDIF), the organisation that invested in the development of the inoculation, said it has received requests from over 20 countries for a total of one billion doses of the vaccine.
Russian scientists have started the third phase of clinical trials of the Sputnik V coronavirus vaccine, which has been highly praised by scientists and epidemiologists from various countries and evaluated by the renowned medical journal Lancet. According to Kirill Dmitriev, CEO of the Russian Direct Investment Fund, thousands of people have voiced their desire to participate in the trials due to the efficacy and safety of Sputnik V.
Russia became the first country to register a vaccine against the coronavirus, which has infected more than 29 million people around the world and killed almost one million. According Industry and Trade Minister Denis Manturov, Russia may start exporting the vaccine already next spring.
Sourse: sputniknews.com
